FHIT:肺动脉高压的新型修饰基因
本研究通过高通量siRNA筛选结合多队列PAH表达数据分析,鉴定出FHIT为BMPR2新型修饰基因。PAH患者中BMPR2与FHIT表达均降低,FHIT降低与内皮和平滑肌细胞功能障碍相关。恩扎妥林通过上调FHIT及抑制miR17-5双重机制改善实验性肺动脉高压。
要点
- FHIT被鉴定为BMPR2新型修饰基因,PAH患者中FHIT表达降低。
- 恩扎妥林通过上调FHIT和抑制miR17-5双机制改善实验性PH。
- Fhit-/-小鼠缺氧性PH加重且常氧下未能恢复。
核心结论
- FHIT是肺动脉高压中新型BMPR2修饰基因,恩扎妥林是老药新用潜在治疗策略。
研究设计与样本
- 研究联合siRNA高通量筛选超过20,000个基因与公共PAH RNA表达数据多队列分析。
- 在PAH患者组织确认基因失调后,进行体外功能研究并在实验性PH模型中测试恩扎妥林。
主要发现
- PAH患者中BMPR2和FHIT表达均降低。
- FHIT降低与内皮和平滑肌细胞功能障碍相关,恩扎妥林可挽救。
- Fhit-/-小鼠缺氧性PH加重且常氧下未能恢复。
- 恩扎妥林在Sugen5416/缺氧/常氧大鼠模型中逆转PH,改善右心室收缩压、右心室肥厚、心脏纤维化和血管重塑。
临床怎么用
- 恩扎妥林作为老药新用,可能成为改善PAH的潜在新型治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Pulmonary arterial hypertension (PAH) is characterized by progressive narrowing of pulmonary arteries, resulting in right heart failure and death. BMPR2 (bone morphogenetic protein receptor type 2) mutations account for most familial PAH forms whereas reduced BMPR2 is present in many idiopathic PAH forms, suggesting dysfunctional BMPR2 signaling to be a key feature of PAH. Modulating BMPR2 signaling is therapeutically promising, yet how BMPR2 is downregulated in PAH is unclear. OBJECTIVES: We intended to identify and pharmaceutically target BMPR2 modifier genes to improve PAH. METHODS: We combined siRNA high-throughput screening of >20,000 genes with a multicohort analysis of publicly available PAH RNA expression data to identify clinically relevant BMPR2 modifiers. After confirming gene dysregulation in tissue from patients with PAH, we determined the functional roles of BMPR2 modifiers in vitro and tested the repurposed drug enzastaurin for its propensity to improve experimental pulmonary hypertension (PH). MEASUREMENTS AND MAIN RESULTS: We discovered FHIT (fragile histidine triad) as a novel BMPR2 modifier. BMPR2 and FHIT expression were reduced in patients with PAH. FHIT reductions were associated with endothelial and smooth muscle cell dysfunction, rescued by enzastaurin through a dual mechanism: upregulation of FHIT as well as miR17-5 repression. Fhit-/- mice had exaggerated hypoxic PH and failed to recover in normoxia. Enzastaurin reversed PH in the Sugen5416/hypoxia/normoxia rat model, by improving right ventricular systolic pressure, right ventricular hypertrophy, cardiac fibrosis, and vascular remodeling. CONCLUSIONS: This study highlights the importance of the novel BMPR2 modifier FHIT in PH and the clinical value of the repurposed drug enzastaurin as a potential novel therapeutic strategy to improve PAH.
引用
- Dannewitz Prosseda S, Tian X, Kuramoto K, et al. FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019. PMID: 30107138. doi:10.1164/rccm.201712-2553OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。